<SEC-DOCUMENT>0001140361-22-023370.txt : 20220617
<SEC-HEADER>0001140361-22-023370.hdr.sgml : 20220617
<ACCEPTANCE-DATETIME>20220617080322
ACCESSION NUMBER:		0001140361-22-023370
CONFORMED SUBMISSION TYPE:	SC 13E3/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20220617
DATE AS OF CHANGE:		20220617
GROUP MEMBERS:		INNOVIVA MERGER SUB, INC.

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Entasis Therapeutics Holdings Inc.
		CENTRAL INDEX KEY:			0001724344
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				824592913
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SC 13E3/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-90651
		FILM NUMBER:		221022419

	BUSINESS ADDRESS:	
		STREET 1:		35 GATEHOUSE DRIVE
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451
		BUSINESS PHONE:		(781) 810-0120

	MAIL ADDRESS:	
		STREET 1:		35 GATEHOUSE DRIVE
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Entasis Therapeutics Ltd
		DATE OF NAME CHANGE:	20171204

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Innoviva, Inc.
		CENTRAL INDEX KEY:			0001080014
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				943265960
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SC 13E3/A

	BUSINESS ADDRESS:	
		STREET 1:		1350 OLD BAYSHORE HIGHWAY
		STREET 2:		SUITE 400
		CITY:			BURLINGAME
		STATE:			CA
		ZIP:			94010
		BUSINESS PHONE:		6502389600

	MAIL ADDRESS:	
		STREET 1:		1350 OLD BAYSHORE HIGHWAY
		STREET 2:		SUITE 400
		CITY:			BURLINGAME
		STATE:			CA
		ZIP:			94010

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	THERAVANCE INC
		DATE OF NAME CHANGE:	20020207

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADVANCED MEDICINE INC
		DATE OF NAME CHANGE:	20000302
</SEC-HEADER>
<DOCUMENT>
<TYPE>SC 13E3/A
<SEQUENCE>1
<FILENAME>ny20004467x2_sc13e3a.htm
<DESCRIPTION>SCHEDULE 13E-3/A
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using EDGARfilings PROfile 8.3.1.0
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">
      <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; margin-left: auto; margin-right: auto;" align="center"><font style="font-size: 14pt;">SECURITIES AND
        EXCHANGE COMMISSION</font></div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold;">Washington, D.C. 20549</div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 18pt; font-weight: bold;">SCHEDULE 13E-3</div>
    <div style="text-align: center; font-weight: bold;">(Rule 13e-100)</div>
    <div style="text-align: center; font-weight: bold;">(Amendment No. 1)</div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">Rule 13e-3 Transaction Statement under Section 13(e)</div>
    <div style="text-align: center; font-weight: bold;">of the Securities Exchange Act of 1934</div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 24pt; font-weight: bold;">ENTASIS THERAPEUTICS HOLDINGS INC.</div>
    <div style="text-align: center; font-weight: bold;">(Name of the Issuer)</div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">Innoviva, Inc.</div>
    <div style="text-align: center; font-weight: bold;">Innoviva Merger Sub, Inc.</div>
    <div style="text-align: center; font-weight: bold;"> (Name of Person(s) Filing Statement)</div>
    <div style="text-align: center; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; font-weight: bold;">Common Stock, $0.001 par value per share</div>
    <div style="text-align: center; font-weight: bold;">(Title of Classes of Securities)</div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">293614103</div>
    <div style="text-align: center; font-weight: bold;">(CUSIP Number of Classes of Securities)</div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">Pavel Raifeld</div>
    <div style="text-align: center; font-weight: bold;">Chief Executive Officer</div>
    <div style="text-align: center; font-weight: bold;">1350 Old Bayshore Highway, Suite 400</div>
    <div style="text-align: center; font-weight: bold;">Burlingame, CA 94010</div>
    <div style="text-align: center; font-weight: bold;">(650) 238-9600</div>
    <div style="text-align: center; font-weight: bold;">(Name, Address and Telephone Number of Person Authorized To Receive Notices and Communications on Behalf of the Person(s) Filing Statement)</div>
    <div><br>
    </div>
    <div style="text-align: center; font-style: italic; font-weight: bold;">With a copy to:</div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">Russell Leaf</div>
    <div style="text-align: center; font-weight: bold;">Jared Fertman</div>
    <div style="text-align: center; font-weight: bold;">Jonathan Kubek</div>
    <div style="text-align: center; font-weight: bold;">Willkie Farr &amp; Gallagher LLP</div>
    <div style="text-align: center; font-weight: bold;">787 7<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> Ave</div>
    <div style="text-align: center; font-weight: bold;">New York, NY 10019</div>
    <div style="text-align: center; font-weight: bold;">(212) 728-8000</div>
    <div><br>
    </div>
    <div style="text-align: justify;">This statement is filed in connection with (check the appropriate box):</div>
    <div><br>
    </div>
    <div style="text-align: justify;">
      <div>
        <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zf4022e0ce9994b85b505e1d9f8199b60" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 36pt; vertical-align: top; align: right;"><font style="color: #000000;">a.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
              <td style="width: 36pt; vertical-align: top; align: right; color: #000000; font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</td>
              <td style="width: auto; vertical-align: top; text-align: justify; color: #000000;">The filing of solicitation materials or an information statement subject to Regulation 14A, Regulation 14C or Rule 13e-3(c) under the Securities Exchange Act
                of 1934.</td>
            </tr>

        </table>
      </div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify;">
      <div>
        <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z76d474ebcf5c47aa98c9e9157eead905" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 36pt; vertical-align: top; align: right;"><font style="color: #000000;">b.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
              <td style="width: 36pt; vertical-align: top; align: right; color: #000000; font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</td>
              <td style="width: auto; vertical-align: top; text-align: justify; color: #000000;">The filing of a registration statement under the Securities Act of 1933.</td>
            </tr>

        </table>
      </div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify;">
      <div>
        <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z97898b40e878479995e90f978048b631" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 36pt; vertical-align: top; align: right;"><font style="color: #000000;">c.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
              <td style="width: 36pt; vertical-align: top; align: right; color: #000000; font-family: 'Segoe UI Symbol', sans-serif;">&#9746;</td>
              <td style="width: auto; vertical-align: top; text-align: justify; color: #000000;">A tender offer.</td>
            </tr>

        </table>
      </div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify;">
      <div>
        <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="ze2ace457cb64461390511ca3bb903e45" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 36pt; vertical-align: top; align: right;"><font style="color: #000000;">d.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
              <td style="width: 36pt; vertical-align: top; align: right; color: #000000; font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</td>
              <td style="width: auto; vertical-align: top; text-align: justify; color: #000000;">None of the above.</td>
            </tr>

        </table>
      </div>
    </div>
    <div><br>
    </div>
    <div>Check the following box if the soliciting materials or information statement referred to in checking box (a) are preliminary copies: <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font></div>
    <div><br>
    </div>
    <div style="text-align: justify;">Check the following box if the filing is a final amendment reporting the results of the transaction: <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font></div>
    <div><br>
    </div>
    <div style="text-align: justify; font-weight: bold;">NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THIS TRANSACTION, PASSED UPON THE MERITS OR FAIRNESS OF THIS TRANSACTION, OR PASSED
      UPON THE ADEQUACY OR ACCURACY OF THE DISCLOSURE IN THIS SCHEDULE 13E-3. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.</div>
    <div style="text-align: justify; font-weight: bold;">
      <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" align="center"> </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <!--PROfilePageNumberReset%Num%2%-%-%-->
    <div style="text-align: center; font-weight: bold;">INTRODUCTION</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">This Amendment No. 1 to Schedule 13e-3 (this &#8220;<u>Amendment</u>&#8221;) is being filed by Innoviva, Inc., a Delaware corporation (&#8220;<u>Parent</u>&#8221; or &#8220;<u>Innoviva</u>&#8221;) and its wholly-owned subsidiary,
      Innoviva Merger Sub, Inc., a Delaware corporation (&#8220;<u>Purchaser</u>&#8221;) and amends and supplements the Rule 13e-3 Transaction Statement on Schedule 13E-3 filed with the Securities and Exchange Commission (the &#8220;<u>SEC</u>&#8221;) on June 7, 2022 (together
      with any amendments and supplements thereto, the &#8220;<u>Schedule 13e-3</u>&#8221;) by Parent and Purchaser and relates to Purchaser&#8217;s offer to purchase all of the outstanding shares of common stock, par value $0.001 per share (the &#8220;<u>Shares</u>&#8221;) of Entasis
      Therapeutics Holdings Inc., a Delaware corporation (&#8220;<u>Entasis</u>&#8221; and, the issuer of the Shares that are the subject of the Rule 13e-3 transaction described below, other than any Shares owned at the commencement of the Offer (as defined below) by
      (i) Innoviva, Purchaser or any other direct or indirect wholly owned subsidiary of Innoviva and (ii) Entasis (or held in Entasis&#8217; treasury)), at a price of $2.20 per Share, net to the seller in cash, without interest and subject to any withholding of
      taxes in accordance with the Merger Agreement (as defined below), upon the terms and subject to the conditions set forth in the Offer to Purchase, dated June 7, 2022 (the &#8220;<u>Offer to Purchase</u>&#8221;) and in the related Letter of Transmittal, which,
      together with any amendments or supplements thereto, collectively constitute the &#8220;<u>Offer</u>.&#8221; The Offer is being made pursuant to that certain Agreement and Plan of Merger, dated as of May 23, 2022, by and among Entasis, Purchaser and Innoviva
      (the &#8220;<u>Merger Agreement</u>&#8221;). The Merger Agreement provides, among other things, for the terms and conditions of the Offer and the subsequent merger of Purchaser with and into Entasis (the &#8220;<u>Merger</u>&#8221;) in accordance with Section 251(h) of the
      Delaware General Corporation Law (the &#8220;<u>DGCL</u>&#8221;).</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">The information contained in the Tender Offer Statement filed under cover of Schedule TO by Innoviva with the SEC on June 7, 2022, (as amended or supplemented from time to time, the &#8220;<u>Schedule TO</u>&#8221;),



      the Offer to Purchase and the Solicitation/Recommendation Statement on Schedule 14D-9 filed by Entasis with the SEC on June 7, 2022 (as amended or supplemented from time to time, the &#8220;<u>Schedule 14D-9</u>&#8221;), is incorporated by reference herein and,
      except as described below, the responses to each item in this Amendment are qualified in their entirety by the information contained in the Schedule TO, the Offer to Purchase and the Schedule 14D-9. The cross references identified herein are being
      supplied pursuant to General Instruction G to Schedule 13E-3 and indicate the location in the Schedule TO and Schedule 14D-9 of the information required to be included in response to the respective Items of this Amendment.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">Any information contained in the documents incorporated herein by reference shall be deemed modified or superseded for purposes of this Amendment to the extent that any information contained herein
      modifies or supersedes such information. All information contained in this Amendment concerning Purchaser, Innoviva or their affiliates has been provided by such person and not by any other person. This Amendment should be read together with the
      original Schedule 13e-3.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">The Schedule 13e-3 is hereby amended and supplemented as follows:</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc80278e18f894d96a358017a04593255" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; align: right;">1.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>The second paragraph of Item 8(c) is hereby amended and restated in its entirety as follows:</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">&#8220;The information set forth in the Offer to Purchase under the headings &#8220;Summary Term Sheet,&#8221; &#8220;The Tender Offer&#8212;11. The Merger Agreement; Other Agreements,&#8221; &#8220;Section 12. Purpose of the Offer; Plans
      for Entasis,&#8221; and &#8220;Section 14. Position of Parent and Purchaser Regarding Fairness of the Offer and the Merger&#8221; is incorporated herein by reference.</div>
    <div style="text-align: justify; margin-left: 72pt;"> <br>
    </div>
    <div style="text-align: justify;">
      <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">2.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;"> Item 15(c) is hereby amended and restated in its entirety as follows:<br>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="margin-left: 72pt;">&#8220;The information set forth in the Offer to Purchase under the heading &#8220;Section 24. Miscellaneous&#8221; is incorporated herein by reference.&#8221; </div>
    </div>
    <div style="text-align: justify; margin-left: 72pt;"> <br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zecfca9a36d204199a08fef3df93168a3" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; align: right;">3.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>The section entitled &#8220;Signatures&#8221; is hereby amended and restated in its entirety as follows:</div>
          </td>
        </tr>

    </table>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">-2-</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <div style="text-align: center; font-weight: bold;">SIGNATURES</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Statement is true, complete and correct.</div>
    <div><br>
    </div>
    <div>Dated: June 17, 2022</div>
    <div> <br>
    </div>
    <div>
      <table id="z6f29caec5bf94771bf9e88b5d4cb2cc0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 50.06%;">
              <div>&#160;</div>
            </td>
            <td colspan="2" rowspan="1">
              <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-weight: bold;">INNOVIVA, INC.</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 50.06%;">&#160;</td>
            <td colspan="2" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50.06%; padding-bottom: 2px;">
              <div>&#160;</div>
            </td>
            <td style="width: 4.99%; padding-bottom: 2px;"><font style="font-family: 'Times New Roman',Times,serif;">By:</font><br>
            </td>
            <td style="width: 44.95%; border-bottom: 2px solid rgb(0, 0, 0);">/s/ <font style="font-family: 'Times New Roman',Times,serif;">Pavel Raifeld</font></td>
          </tr>
          <tr>
            <td style="width: 50.06%;">
              <div>&#160;</div>
            </td>
            <td style="width: 4.99%;"><font style="font-family: 'Times New Roman',Times,serif;">Name:</font></td>
            <td style="width: 44.95%;"> <font style="font-family: 'Times New Roman',Times,serif;">Pavel Raifeld</font></td>
          </tr>
          <tr>
            <td style="width: 50.06%;">
              <div>&#160;</div>
            </td>
            <td style="width: 4.99%;"><font style="font-family: 'Times New Roman',Times,serif;">Title:</font></td>
            <td style="width: 44.95%;">
              <div style="text-align: left;"><font style="font-family: 'Times New Roman',Times,serif;">Chief Executive Officer</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div style="margin-left: 216pt; font-weight: bold;"><br>
    </div>
    <div>
      <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 50.06%;">
              <div>&#160;</div>
            </td>
            <td colspan="2" rowspan="1">
              <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-weight: bold;">
                <div style="font-weight: bold;">INNOVIVA MERGER SUB, INC.</div>
              </div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 50.06%;">&#160;</td>
            <td colspan="2" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50.06%; padding-bottom: 2px;">
              <div>&#160;</div>
            </td>
            <td style="width: 4.99%; padding-bottom: 2px;"><font style="font-family: 'Times New Roman',Times,serif;">By:</font><br>
            </td>
            <td style="width: 44.95%; border-bottom: 2px solid rgb(0, 0, 0);">/s/ <font style="font-family: 'Times New Roman',Times,serif;">Pavel Raifeld</font></td>
          </tr>
          <tr>
            <td style="width: 50.06%;">
              <div>&#160;</div>
            </td>
            <td style="width: 4.99%;"><font style="font-family: 'Times New Roman',Times,serif;">Name:</font></td>
            <td style="width: 44.95%;"> <font style="font-family: 'Times New Roman',Times,serif;">Pavel Raifeld</font></td>
          </tr>
          <tr>
            <td style="width: 50.06%;">
              <div>&#160;</div>
            </td>
            <td style="width: 4.99%;"><font style="font-family: 'Times New Roman',Times,serif;">Title:</font></td>
            <td style="width: 44.95%;">
              <div style="text-align: left;">President</div>
            </td>
          </tr>

      </table>
    </div>
    <div style="margin-left: 216pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <br>
    </div>
    <div style="text-align: center;">-3- &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman',Times,serif;"><br>
      </font></div>
    <div>
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
